New prospects in the treatment of diabetes mellitus
Cardiovascular complications, a major cause for disability and morbidity in diabetes mellitus (DM), constitute the greatest threat of the diabetes epidemic. Glycemic stability within the therapeutic targets is a prerequisite to prevention of micro- and macrovascular complications of DM. Traditional...
Guardado en:
Autores principales: | Minara Shamkhalovna Shamkhalova, Natalya Petrovna Trubitsyna, Marina Vladimirovna Shestakova |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f1120e4cab23493e98a2446c72d6adc8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
por: Editorial team Diabetes Mellitus
Publicado: (2012) -
Inсretin-based therapy in patients with type 2 diabetes and chronic kidney disease
por: Minara Shamkhalovna Shamkhalova, et al.
Publicado: (2012) -
Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
por: Elena Valer'evna Biryukova
Publicado: (2014) -
Russian Association of Endocrinologists reports commencement of Trajenta clinical use
por: Editorial team Diabetes Mellitus
Publicado: (2012) -
Vildagliptin and its role in the treatment of diabetes mellitus
por: Yury Shavkatovich Khalimov
Publicado: (2010)